Transpharmation Ltd. is a privately held preclinical Contract Research Organisation with dual North American and European operations. The company positions itself as a global leader in translational biology, with a stated mission to accelerate pharmaceutical drug discovery programmes to the clinic through high-quality, clinically relevant preclinical research services.

A defining scientific differentiator of Transpharmation is its capability to assess naturally developing, age-related disease in animal models — including Alzheimer’s-like cognitive decline, osteoarthritic pain, and other spontaneous conditions — rather than relying exclusively on pharmacologically or surgically induced disease models. This approach is positioned as producing more clinically translatable preclinical data, addressing a well-recognised criticism of conventional induced disease models whose relevance to human pathology is often limited.

In October 2026, Transpharmation announced a strategic acquisition of OrganoTherapeutics SARL, a Luxembourg-based organoid technology company. This acquisition meaningfully extends Transpharmation’s preclinical capabilities from in vivo rodent models into human iPSC-derived brain organoid technology — a translational platform that enables disease modelling and drug screening in human neural tissue without animal use, directly complementing the company’s existing in vivo portfolio.

The company has an active publication record and participates in major scientific conferences including IASP (International Association for the Study of Pain) and the Animal Health, Nutrition and Technology Innovation (AHNTI) USA Summit, reflecting engagement across both human pharmaceutical and veterinary research communities.

Key Products and Services

Pain Research

• Inflammatory Pain — validated rodent models of peripheral and central inflammatory pain including carrageenan, CFA, and monoiodoacetate (MIA) models; electrophysiology, von Frey filament, and operant pain assessment platforms
• Neuropathic Pain — sciatic nerve ligation (SNL), spared nerve injury (SNI), and diabetic neuropathy models; mechanical allodynia, thermal hyperalgesia, and operant pain behaviour assessment
• Osteoarthritis — spontaneously developing osteoarthritic pain models using naturally aged animals; MIA-induced OA models; weight bearing and gait analysis
• Migraine — trigeminovascular pain models for migraine mechanism and drug efficacy evaluation

Neurodegenerative and Cognitive Disorders

• Alzheimer’s Disease — naturally developing cognitive decline models using aged animals; transgenic AD models; cognitive assessment via Morris water maze, novel object recognition, and operant platforms; amyloid and tau biomarker endpoints
• Parkinson’s Disease — dopaminergic neurotoxin models; motor function assessment; neurochemical biomarkers
• Cognitive Assessment — comprehensive battery of validated rodent cognitive tests including spatial memory, learning, working memory, and executive function tasks
• Multiple Sclerosis — EAE model; motor function, inflammation, and demyelination endpoints

CNS Disorders

• Depression and Anxiety — forced swim test, elevated plus maze, sucrose preference, novelty suppressed feeding, and chronic mild stress models
• Schizophrenia — prepulse inhibition, latent inhibition, and social interaction models
• Epilepsy — acute seizure threshold and chronic epilepsy models; EEG monitoring
• Essential Tremor — harmaline-induced tremor and genetic tremor models
• Abuse Liability and Substance Use Disorders — conditioned place preference, self-administration, and sensitisation models
• Psychedelics — head twitch response, 5-HT2A receptor-mediated behaviour, and social interaction paradigms for psychedelic and psychoplastogen drug evaluation

Metabolic and Systemic Disorders

• Metabolic Disorders — diet-induced obesity and streptozotocin models for metabolic syndrome and diabetes drug evaluation
• Inflammation — systemic and localised inflammation models
• Dermatology — topical and systemic dermatology efficacy models

Pharmacology and Bioanalysis

• PK/PD Studies — pharmacokinetic and pharmacodynamic study design and execution in rodent and non-rodent species
• PK-Bridge — a service linking preclinical PK data to clinical predictions, supporting translational dose selection and IND-enabling programme decisions
• Bioanalytical Studies — sample analysis for PK/TK studies across plasma and tissue matrices
• Molecular Biomarkers — protein, gene expression, and neurochemical biomarker quantification in CNS and peripheral tissues

Specialist Platforms

• EEG — continuous and event-related EEG recording in freely moving rodents for epilepsy, sleep, cognitive, and CNS drug safety studies
• Operant Platform — operant conditioning-based pain and cognitive assessment paradigms providing objective, voluntary endpoint measurement
• SPIDAR — a proprietary platform for spontaneous pain assessment in rodents
• Imaging — in vivo small animal imaging including MRI, PET, and optical imaging for neurological and oncological endpoint assessment
• PXB Mouse Studies — chimeric mouse with humanised liver for human-relevant metabolism and hepatotoxicity studies

Organoid Technology (via OrganoTherapeutics acquisition)

• Human iPSC-derived brain organoid disease modelling and drug screening, providing human neural tissue-based translational research capability complementary to the in vivo portfolio

Veterinary Research

• Preclinical efficacy and safety research services in animal health indications

Transpharmation occupies a well-defined specialist position in the preclinical CRO landscape as a neuroscience-focused organisation with a genuine scientific differentiator — the use of naturally developing, age-related disease models — that addresses one of the most persistent criticisms of conventional preclinical neuroscience research: the poor translatability of pharmacologically induced disease to human pathology. The October 2026 acquisition of OrganoTherapeutics SARL is strategically significant, adding human iPSC-derived brain organoid technology to a predominantly in vivo portfolio and positioning Transpharmation to serve sponsors seeking a combined in vivo and human-relevant in vitro research offering within a single CRO relationship. The company’s dual North American and European operational footprint, combined with an active scientific publication record and conference presence, supports a credible positioning as a translational neuroscience research partner of international standing.